Buy Abionyx Pharma Stock in 2026: Share Price, Business and Analysis

Looking to buy Abionyx Pharma stock? This profile covers the share price of this French biotech listed on Euronext Growth Paris, its therapeutic development programme, its financial position, the strengths and risks of the investment case, and then the practical method for buying this micro-cap stock from France.

Abionyx Pharma Share Price

The live quote is available from your broker or on the leading financial platforms; the stock’s liquidity is very low and bid-ask spreads are wide — two factors to take into account before placing any order.

Market data and history, updated automatically

ABIONYX Pharma SAABNX.PA · Paris
1,56 €-6,71 %
Clôture précédente1,67 €
Plus haut du jour1,56 €
Plus bas du jour1,53 €
Plus haut 52 semaines4,60 €
Plus bas 52 semaines1,41 €
Volume17 517
Capitalisation68 M
Rendement du dividende0,00 %
Objectif moyen des analystes9,75 €
Mis à jour le 2026-11-19 12:45:20 · Source : Yahoo · Données indicatives, ne constituent pas un conseil en investissement.

Résultats annuels — ABIONYX Pharma SA
Exercice clos leChiffre d’affairesRésultat net
2025-12-314,1 M €-5,5 M €
2024-12-314,6 M €-4,4 M €
2023-12-314,6 M €-3,5 M €
2022-12-315,3 M €-4,2 M €
Source : Yahoo Finance · Collecté le 2026-11-18 14:45:26 UTC · Données historiques indicatives, non temps réel.

Historique des dividendes — ABNX.PA

Données historiques indisponibles pour ce titre.

Source: Yahoo Finance, data collected by the server (collection date shown under each block). Indicative data only; it does not constitute investment advice.

Our profile of Acadia Healthcare stock is a useful complement to this analysis if you are comparing several healthcare stocks.

Abionyx Pharma Stock Profile

CompanyAbionyx Pharma S.A.
MarketEuronext Growth Paris
Ticker / SymbolABIO
HeadquartersFrance
SectorBiotechnology: developing a treatment for neuropathic pain
Trading currencyEuro (EUR)
Financial year endDecember 31
PEA eligibilityYes (French issuer)

About Abionyx Pharma: Business and Programme

A biotech focused on neuropathic pain

Abionyx Pharma is a French biotechnology company dedicated to developing a treatment for chronic neuropathic pain — pain caused by nerve damage, for which current treatments only partly relieve some patients. The programme is based on a biologically derived molecule developed by the company, which has gone through preclinical research and regulated clinical development.

A step-by-step clinical development model

The progress of a biotech of this size is measured in milestones: approval of trials by the health authorities, patient recruitment, efficacy and safety results, and then possible industry partnerships to fund the most expensive phases. Each milestone reached can reset the valuation; each delay can erode it for a long time. This is the mechanism common to biotech stocks listed on Euronext Growth, a segment of the Paris stock market with very specific profiles.

A tiny market cap and tight governance

Abionyx Pharma is one of the smallest companies by market capitalisation on the French market: its shareholder base is concentrated around the founders and long-term shareholders, the free float is small, and trading volumes are measured in small quantities. This set-up shields the company from the volatility of institutional flows, but makes it harder for a minority shareholder to exit a position.

Abionyx Pharma Results and Financial Data

Like most clinical-stage biotechs, Abionyx Pharma does not yet generate significant commercial revenue: its accounts are read mainly through the research and development expense line and the available cash, which sets how long it can go before it may need new financing.

Exchange and tickerParis — ABNX.PA
SectorHealthcare

Yahoo Finance — data checked on October 23, 2026: share price and fundamentals. Market data is indicative and does not constitute investment advice.

To put precise figures on the situation — net cash, annual results, progress of the clinical programme — check the latest reports published on the company’s investor relations page: for a company of this size, every set of accounts can change how the case is read, and it would be unwise to extrapolate from old figures.

Abionyx Pharma Stock Dividend

Abionyx Pharma does not pay a dividend: the company devotes its resources to funding its therapeutic programme and has not distributed any profits.

The only potential source of returns is share price growth, driven by clinical results and capital events. This profile places the stock among speculative niche stocks, unsuitable for an income strategy or for a large portfolio allocation.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Should You Buy Abionyx Pharma Stock in 2026?

Strengths:

  • A programme targeting an unmet medical need: treatment-resistant chronic neuropathic pain.
  • PEA eligibility and a euro listing on Euronext Growth Paris.
  • Small market cap: positive clinical milestones can have an amplified effect on the share price.

Points to watch:

  • Micro-cap with almost no liquidity: hard to sell without a discount.
  • High scientific and regulatory risk: a failed clinical phase can wipe out the valuation.
  • Recurring funding needs: every capital raise dilutes existing shareholders.

Abionyx Pharma is a stock for well-informed investors: it requires reading the clinical and financial announcements directly and committing only a token share of your capital. Compare this level of risk with other profiles in our ranking of the best stocks before making any decision.

Fundamental and Technical Analysis of Abionyx Pharma Stock

Fundamental analysis

Two sets of data drive the case: net cash and the date it will run out, and the progress of the clinical programme (approvals, patients enrolled, expected results). A biotech with no revenue is judged on its ability to reach the next milestone without excessive dilution: read the half-year accounts and progress announcements.

Technical analysis

Very low volumes make classic chart analysis unreliable: price moves are concentrated around announcements and shareholder meetings. The most useful reference point remains the valuation from the latest capital raises, rather than chart patterns.

How to Buy Abionyx Pharma Stock

  1. Choose a broker that gives access to Euronext Growth Paris: compare fees in our selection of the best stock brokers.
  2. Open an account — the stock, issued by a French company, is eligible for the PEA as well as a securities account — and verify your identity.
  3. Always place a limit order: without this precaution, a market order on such an illiquid stock can be filled at a price far from the last quote.
  4. Follow the clinical and financial announcements, the only events that move the share price.

To get each step right, our complete guide to buying shares explains how to choose an account, place the order and monitor your position.

Frequently Asked Questions About Abionyx Pharma Stock

Which exchange is Abionyx Pharma stock listed on?

On Euronext Growth Paris, under the ticker ABIO, in euros.

Does Abionyx Pharma pay a dividend?

No. The company is funding its therapeutic programme and does not distribute profits.

Can you hold Abionyx Pharma stock in a PEA?

Yes. The issuer is a French company: the stock is eligible for the PEA as well as an ordinary securities account.

What is the main risk with this stock?

The triple risk facing very small biotechs: possible clinical failure, almost no liquidity and dilution from successive capital raises.

What is the company’s programme based on?

On a treatment for chronic neuropathic pain in clinical development; progress can only be tracked through the company’s official announcements.

Disclaimer: this content is for information only and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not a reliable indicator of future performance.

Suivez-nous sur Telegram